Robin Dore, PA
Medical · McKinney, TXNPI 1114208824
Payments from drug & device makers
Across 265 payments — averaging $24.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- AbbVie$986
- Novo Nordisk$379
- Merck$312
- Biohaven Pharmaceuticals, Inc.$203
- Pfizer$190
- plus $2K from 29 others
What the payments were for
- Consulting fees$2,53038%
- Food & beverage$4,06962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 2 | $2,541 |
| AbbVie | 73 | $986 |
| Novo Nordisk | 28 | $379 |
| Merck | 22 | $312 |
| Biohaven Pharmaceuticals, Inc. | 14 | $203 |
| Pfizer | 12 | $190 |
| Novartis | 3 | $186 |
| GSK | 11 | $151 |
| Clarus Therapeutics Inc. | 9 | $146 |
| Esperion Therapeutics, Inc. | 7 | $144 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $142 |
| Johnson & Johnson(2 entities) | 7 | $123 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $112 |
| Eisai Inc. | 5 | $101 |
| Lilly USA, LLC | 7 | $100 |
| Jazz Pharmaceuticals Inc. | 5 | $96 |
| Amgen(2 entities) | 6 | $94 |
| AstraZeneca(2 entities) | 5 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Boehringer Ingelheim | 3 | $60 |
| Abbott | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Amarin Pharma, Inc. | 4 | $48 |
| Antares Pharma, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $15 |
| Medtronic | 1 | $14 |
| Nevro Corp. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $11 |
| Itamar Medical Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEVZARA$2,530
How this compares
$6,599 in reported general payments places this provider in the 85th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $81,552 |
| MounjaroTirzepatide | 46 | $50,160 |
| JardianceEmpagliflozin | 27 | $36,581 |
| JanuviaSitagliptin Phosphate | 19 | $28,435 |
| TrulicityDulaglutide | 14 | $25,245 |
| EliquisApixaban | 24 | $19,485 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $17,096 |
| XareltoRivaroxaban | 16 | $13,288 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $7,741 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,177 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,937 |
| Levothyroxine Sodium | 277 | $3,677 |
| Testosterone Cypionate | 65 | $2,977 |
| Rosuvastatin Calcium | 175 | $2,333 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 96 | $2,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $379 | $81,55267 claims |
| Lilly USA, LLCMounjaro, Trulicity | $100 | $75,40560 claims |
| Boehringer IngelheimJardiance | $60 | $36,58127 claims |
| MerckJanuvia | $312 | $28,43519 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $151 | $21,27336 claims |
| PfizerEliquis | $190 | $19,48524 claims |
| Johnson & JohnsonXarelto | $123 | $13,28816 claims |
| AstraZenecaSymbicort | $88 | $3,93713 claims |
| AbbVieSynthroid, Armour Thyroid | $986 | $2,25747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,490 medical providers in Texas.
Other medical in McKinney
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.